Pfizer Receivables Turnover vs Cash Flow Per Share Analysis
PFE Stock | USD 25.26 1.01 3.84% |
Trend analysis of Pfizer Inc balance sheet accounts such as Total Stockholder Equity of 46.9 B, Property Plant And Equipment Net of 11.3 B, Net Debt of 75.8 B or Retained Earnings of 124.3 B provides information on Pfizer's total assets, liabilities, and equity, which is the actual value of Pfizer Inc to its prevalent stockholders. By breaking down trends over time using Pfizer balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Pfizer |
About Pfizer Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Pfizer Inc at a specified time, usually calculated after every quarter, six months, or one year. Pfizer Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Pfizer and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Pfizer currently owns. An asset can also be divided into two categories, current and non-current.
Pfizer Balance Sheet Chart
Pfizer Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Pfizer Inc uses and utilizes its capital. It also shows what exactly a company owns and owes.
At present, Pfizer's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 28.9 B, whereas Property Plant And Equipment Net is forecasted to decline to about 11.3 B. Add Fundamental
Total Assets
Total assets refers to the total amount of Pfizer assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Pfizer Inc books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Pfizer balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Pfizer Inc are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Pfizer's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pfizer Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. At present, Pfizer's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 240.8 B, whereas Tax Provision is projected to grow to (1.1 B).
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 50.5B | 66.0B | 29.3B | 30.4B | Total Revenue | 81.3B | 100.3B | 58.5B | 39.5B |
Pfizer fundamental ratios Correlations
Click cells to compare fundamentals
Pfizer Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pfizer fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 167.5B | 154.2B | 181.5B | 197.2B | 226.5B | 237.8B | |
Short Long Term Debt Total | 52.1B | 38.3B | 37.0B | 34.9B | 75.0B | 78.8B | |
Total Current Liabilities | 37.3B | 25.9B | 42.7B | 42.1B | 47.8B | 50.2B | |
Total Stockholder Equity | 63.1B | 63.2B | 77.2B | 95.7B | 89.0B | 46.9B | |
Property Plant And Equipment Net | 14.0B | 13.9B | 14.9B | 16.3B | 18.9B | 11.3B | |
Net Debt | 50.8B | 36.5B | 35.1B | 34.5B | 72.2B | 75.8B | |
Retained Earnings | 97.7B | 96.8B | 103.4B | 125.7B | 118.4B | 124.3B | |
Cash | 1.3B | 1.8B | 1.9B | 416M | 2.9B | 2.0B | |
Non Current Assets Total | 134.7B | 119.2B | 121.8B | 145.9B | 183.2B | 192.3B | |
Non Currrent Assets Other | 4.5B | 4.6B | 7.7B | 13.2B | 9.1B | 5.3B | |
Cash And Short Term Investments | 9.8B | 12.2B | 31.1B | 22.7B | 12.7B | 14.9B | |
Net Receivables | 12.1B | 11.2B | 15.7B | 14.5B | 11.2B | 8.7B | |
Common Stock Shares Outstanding | 5.7B | 5.6B | 5.7B | 5.7B | 5.7B | 5.7B | |
Liabilities And Stockholders Equity | 167.5B | 154.2B | 181.5B | 197.2B | 226.5B | 237.8B | |
Non Current Liabilities Total | 66.7B | 64.8B | 61.3B | 59.2B | 89.4B | 93.9B | |
Inventory | 8.3B | 8.0B | 9.1B | 9.0B | 10.2B | 5.2B | |
Other Current Assets | 2.6B | 3.4B | 3.8B | 5.0B | 9.3B | 9.7B | |
Other Stockholder Equity | (23.4B) | (22.3B) | (20.8B) | (22.2B) | (21.9B) | (20.8B) | |
Total Liab | 104.0B | 90.8B | 104.0B | 101.3B | 137.2B | 144.1B | |
Property Plant And Equipment Gross | 14.0B | 28.4B | 30.0B | 31.4B | 35.0B | 36.7B | |
Total Current Assets | 32.8B | 35.1B | 59.7B | 51.3B | 43.3B | 32.2B | |
Short Term Debt | 16.2B | 2.7B | 2.2B | 2.9B | 10.9B | 5.7B | |
Intangible Assets | 35.4B | 28.5B | 25.1B | 43.4B | 64.9B | 68.1B | |
Property Plant Equipment | 14.0B | 13.9B | 14.9B | 16.3B | 18.9B | 11.3B | |
Accounts Payable | 4.2B | 4.3B | 5.6B | 6.8B | 6.7B | 7.0B | |
Accumulated Other Comprehensive Income | (11.6B) | (11.7B) | (5.9B) | (8.3B) | (8.0B) | (7.6B) | |
Common Stock Total Equity | 468M | 470M | 473M | 476M | 478M | 474.0M | |
Short Term Investments | 8.5B | 10.4B | 29.1B | 22.3B | 9.8B | 9.3B | |
Capital Stock | 468M | 470M | 473M | 476M | 478M | 474.0M | |
Common Stock | 468M | 470M | 473M | 476M | 478M | 474.0M | |
Other Liab | 29.7B | 26.6B | 22.6B | 23.3B | 26.9B | 22.1B | |
Other Assets | 4.2B | 4.3B | 5.6B | 6.8B | 6.7B | 5.0B | |
Long Term Debt | 36.0B | 37.1B | 36.2B | 32.9B | 60.5B | 63.5B | |
Good Will | 58.7B | 49.6B | 49.2B | 51.4B | 67.8B | 40.7B | |
Treasury Stock | (110.8B) | (111.0B) | (111.4B) | (114.0B) | (114.5B) | (108.8B) | |
Current Deferred Revenue | 5.8B | 6.3B | 3.1B | 2.5B | 2.7B | 3.9B | |
Net Tangible Assets | (30.9B) | 63.2B | 77.2B | 95.7B | 89.0B | 93.5B |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
CEOs Directory Screen CEOs from public companies around the world |
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Dividend Share 1.64 | Earnings Share 0.37 | Revenue Per Share 10.366 | Quarterly Revenue Growth (0.41) |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.